CERAMENT^® has two key properties that enables it to play a key role in the management of such indications. These properties are

• the ability to remodel into host bone within 6 to 12 months
• the ability to locally deliver into bone voids drugs that can be used to treat bone disease

The ability of CERAMENT to deliver drugs into bone voids has led to the successful development and commercialization of  CERAMENT^®|G* and CERAMENT^® V* in Europe. CERAMENT|G and CERAMENT V deliver gentamicin and vancomycin respectively.

BONESUPPORT AB has a number of new product candidates in pre-clinical development.

*CERAMENT|G and CERAMENT V are only available outside the United States and have not been approved or cleared for marketing by the United States Food & Drug Administration